219 related articles for article (PubMed ID: 28039512)
1. Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Cohen YC; Zuckerman T; Yeshurun M; Perez G; Magen H; Henig I; Levi I; Shargian L; Trestman S; Rouvio U; Naparstek E; Ganon-Elazar E; Avivi I; Ram R
Ann Hematol; 2017 Feb; 96(2):271-278. PubMed ID: 28039512
[TBL] [Abstract][Full Text] [Related]
2. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.
Bashir Q; Chamoun K; Milton DR; Khan M; Ahmed S; Mehta R; Popat UR; Kebriaei P; Nieto Y; Oran B; Ciurea SO; Hosing C; Khouri I; Patel K; Manasanch EE; Lee HC; Orlowski RZ; Champlin RE; Qazilbash MH
Leuk Lymphoma; 2019 Dec; 60(14):3536-3543. PubMed ID: 31282244
[TBL] [Abstract][Full Text] [Related]
4. The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea.
Lee HS; Min CK; Lee JJ; Kim K; Kim SJ; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC; Lee MH;
Ann Hematol; 2016 May; 95(6):911-9. PubMed ID: 27052989
[TBL] [Abstract][Full Text] [Related]
5. Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age.
Dhakal B; Nelson A; Guru Murthy GS; Fraser R; Eastwood D; Hamadani M; Pasquini M; D'Souza A; Hari P
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):165-172. PubMed ID: 28159578
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
[TBL] [Abstract][Full Text] [Related]
8. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
9. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
10. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
11. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.
Varma A; Biritxinaga L; Saliba RM; Stich M; Jauch SF; Afrough A; Honhar M; Popat UR; Shafi MA; Shah N; Bashir Q; Dinh Y; Hosing C; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2017 Apr; 23(4):581-587. PubMed ID: 28063964
[TBL] [Abstract][Full Text] [Related]
12. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.
Arora M; McGlave PB; Burns LJ; Miller JS; Barke JN; Defor TE; Weisdorf DJ
Bone Marrow Transplant; 2005 Jun; 35(12):1133-40. PubMed ID: 15834435
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Kumar L; Sahoo RK; Kumar S; Baa AK; Tansir G; Pathak N; Malik PS; Sharma OD; Mathew A; Jha A; Gupta R; Sharma A; Biswas A; Kumar R; Thulkar S; Malik S; Dutt A;
Leuk Lymphoma; 2023 Feb; 64(2):378-387. PubMed ID: 36416679
[TBL] [Abstract][Full Text] [Related]
14. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
Graff TM; Singavi AK; Schmidt W; Eastwood D; Drobyski WR; Horowitz M; Palmer J; Pasquini M; Rizzo DJ; Saber W; Hari P; Fenske TS
Bone Marrow Transplant; 2015 Jul; 50(7):947-53. PubMed ID: 25867651
[TBL] [Abstract][Full Text] [Related]
15. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study.
Antlanger M; Dust T; Reiter T; Böhm A; Lamm WW; Gornicec M; Willenbacher E; Nachbaur D; Weger R; Rabitsch W; Rasoul-Rockenschaub S; Worel N; Lechner D; Greinix H; Keil F; Gisslinger H; Agis H; Krauth MT
BMC Cancer; 2018 Oct; 18(1):1008. PubMed ID: 30342509
[TBL] [Abstract][Full Text] [Related]
16. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
18. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
[TBL] [Abstract][Full Text] [Related]
19. Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre.
Fernyhough LJ; Hock BD; Taylor J; Pearson J; Ganly P
Intern Med J; 2013 Feb; 43(2):130-7. PubMed ID: 22530659
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.
Jacobs RW; Saliba RM; Sasaki K; Farhan S; Armas A; Shah ND; Bashir Q; Qureshi S; Rondon G; Hosing C; Popat U; Parmar S; Shah JJ; Wang M; Weber DM; Thomas SK; Orlowski RZ; Champlin RE; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):36-42. PubMed ID: 26702475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
